Plain language summary
======================

It is estimated that type 2 diabetes mellitus (T2DM) affects 422 million adults worldwide representing significant global health burden. Chronic therapy, disease burden, and well-known complications of T2DM affect all aspects of everyday life. Moreover, T2DM is often associated with multiple comorbidities which impair quality of life.

One such comorbidity is obstructive sleep apnea (OSA) which is a well-established disease playing a major role in the pathophysiology of metabolic disorders. It has been already shown that the prevalence of OSA is higher among patients with T2DM compared to general population and that OSA influences glucose regulation. However, the impact of OSA on quality of life in T2DM patients was not thoroughly investigated.

Our questionnaire-based study aimed to investigate differences in quality of life among T2DM patients with different risk for OSA. Since full-night polysomnography, which is a gold standard for OSA diagnosis, is a time-consuming and an expensive method, and available questionnaires offer acceptable sensitivity and specificity for OSA prediction, it is reasonable to use such tools.

T2DM patients from our study with high risk for OSA exhibited lower values in all aspects of quality of life. This finding was confirmed after analysis adjustments for several confounding variables such as body mass index and HbA1c which are well-known influential factors.

Our study emphasizes the importance of routine measurements of quality of life among T2DM patients, especially when associated with comorbidities such as OSA.

Introduction
============

Type 2 diabetes mellitus (T2DM) and obstructive sleep apnea (OSA) are highly prevalent chronic diseases with numerous complications and significant morbidity. It is estimated that almost every 12th adult in the world suffers from diabetes, while at least 14% of male and 5% of female population have OSA.[@b1-ppa-12-765],[@b2-ppa-12-765] Furthermore, specific subgroups have even higher prevalence based on the presence of acclaimed risk factors.[@b3-ppa-12-765] Due to increasing prevalence, adverse health impact, and enormous economic burden, T2DM and OSA represent burgeoning global health issue.[@b1-ppa-12-765],[@b2-ppa-12-765]

OSA is a most common sleep-related breathing disorder characterized by reversible upper airway collapse leading to intermittent airflow cessation. Major pathophysiological effects of such events are intermittent hypoxia, sleep fragmentation, cortical arousals, and sympathetic excitation, which make patients with OSA prone to development of numerous long-term complications. Except cardiovascular and cerebrovascular disorders, metabolic dysfunction is a well-known complication of OSA.[@b4-ppa-12-765],[@b5-ppa-12-765] Previous studies have showed increased prevalence and incidence of T2DM in OSA patients compared to general population.[@b6-ppa-12-765],[@b7-ppa-12-765] Notably, in a large multiethnic study, prevalence of T2DM increased with worsening OSA severity.[@b8-ppa-12-765] In fact, it seems that autonomic neuropathy can affect respiratory control and upper airway patency while asleep, leading to bidirectional effects of OSA and T2DM.[@b9-ppa-12-765]

Aforementioned findings indicate that patients with T2DM should be screened for OSA symptoms. Consequently, it has been shown that most of the primary care diabetic patients have high risk for OSA.[@b10-ppa-12-765] Available questionnaires for OSA risk such as STOP (Snoring, Tiredness, Observed apnea, and high blood Pressure) questionnaire offer sufficient strength in predicting OSA.[@b11-ppa-12-765] Accordingly, polysomnographically based studies confirm increased prevalence of OSA among T2DM population.[@b12-ppa-12-765] Moreover, these findings are highlighted by the fact that even in the general population most of the individuals with OSA are undiagnosed.[@b10-ppa-12-765] Finally, available studies support the evidence for independent association of increasing OSA severity with higher glycated hemoglobin (HbA1c) values.[@b8-ppa-12-765],[@b13-ppa-12-765]

Health-related quality of life (HRQoL) in patients with chronic disease is an essential clinical outcome with significant health implications. Disease chronicity, numerous complications, and long-term therapy have significant physical and psychological consequences affecting individual's everyday functioning and well-being.[@b14-ppa-12-765]

Previous studies have showed adverse effects of OSA on HRQoL.[@b15-ppa-12-765] OSA-related symptoms such as excessive daytime sleepiness, nocturia, morning headaches, cognitive dysfunction, and impotence disturb daily activities and welfare.[@b4-ppa-12-765] Importantly, occupational and traffic accidents are common in OSA.[@b15-ppa-12-765]

Likewise, numerous studies have observed lower overall HRQoL in diabetic patients.[@b16-ppa-12-765] Widely familiar diabetes-related symptoms, negative pathophysiologic effects, and multiple diabetes-related complications along with multiple comorbidities have significant everyday consequences.[@b1-ppa-12-765] Accordingly, it has been shown that patients with worse glycemic control exhibit decreased HRQoL, yet available studies are inconsistent.[@b17-ppa-12-765] Importantly, decreased HRQoL is associated with increased mortality in patients with T2DM.[@b18-ppa-12-765]

Additionally, both OSA and T2DM patients have increased prevalence and incidence of multiple comorbidities which certainly deteriorate HRQoL, such as depression, cerebrovascular, and cardiovascular disorders.[@b4-ppa-12-765],[@b19-ppa-12-765],[@b20-ppa-12-765] Moreover, obesity, which is a major risk factor for OSA and T2DM, impairs HRQoL.[@b21-ppa-12-765]

Important determinant of HRQoL is quality of sleep.[@b22-ppa-12-765] It seems that sleep quality plays an important role in "circulus vitiosus" of T2DM and sleep-disordered breathing. Previous studies suggest that most diabetic patients have impaired sleep quality.[@b23-ppa-12-765] Moreover, there are evidences that decreased sleep amount and impaired sleep quality deteriorate glycemic control.[@b24-ppa-12-765] Since sleep quality markedly contributes to HRQoL, it is reasonable that concomitant OSA lowers HRQoL in diabetic patients.[@b12-ppa-12-765],[@b22-ppa-12-765] However, whether the presence of high risk for OSA has aggravational impact on HRQoL in diabetic patients still remains to be elucidated.

Therefore, main goal of our study was to evaluate risk for OSA in addition to HRQoL in T2DM patients.

Patients and methods
====================

Study design
------------

This cross-sectional, questionnaire-based study was conducted in Center for Diabetes of University Hospital of Split over a period from April to September 2017. All participants were informed about procedures, course, and aim of this study.

Ethical considerations
----------------------

Written informed consent was obtained from all individual participants included in the study. The study protocol was approved by the Ethics Committee of the University of Split School of Medicine. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Subjects
--------

Study sample of 466 patients on regular visit to diabetologist were enrolled in the study. Inclusion criteria were having T2DM, aged 18--75 years, and receiving stable medication therapy for 3 months prior to the research. Exclusion criteria were prior diagnosis of OSA or other sleep-related breathing disorder; type 1 diabetes mellitus; gestational diabetes or other type of diabetes mellitus; severe cardiovascular, pulmonary, renal, neurologic, or psychiatric disease; active malignant disease; and alcohol or substance abuse.

Clinical assessment
-------------------

Anthropometric measurements were proceeded according to the conventional medical standards. All patients on regular visit brought results of HbA1c values that are not older than 7 days. Detailed medical history was obtained from anamnestical data, medical records, and self-reports. After regular clinical evaluation, all patients were asked to complete questionnaires for assessment of OSA-related variables and HRQoL.

OSA-related variables
---------------------

Risk for OSA was determined with STOP questionnaire, while Epworth Sleepiness Scale (ESS) was used to assess daytime sleepiness.

ESS comprises 8 questions related to likelihood of falling asleep in ordinary daily situations which patients score on a scale from 0 (never) to 3 (high likelihood). Higher sum of 8-question score, ranging from 0 to 24, indicates increased propensity to sleep.[@b25-ppa-12-765] Subjects were classified into 3 groups based on ESS score (≤6 normal; 7 and 8 moderate; ≥9 severe). Validated Croatian version of the ESS had been used.[@b11-ppa-12-765]

STOP questionnaire is a special 4-item survey primarily designed to assess the risk for OSA in surgical patients.[@b26-ppa-12-765] It contains 4 questions related to snoring, daytime tiredness, observed apnea, and blood pressure in yes/no format. Patients with 1 positive answer were classified as having low risk for OSA and patients with 2 or more positive answers were classified as having high risk. Validated Croatian version of the STOP questionnaire with sensitivity of 96% and specificity of 83% had been used.[@b11-ppa-12-765] Additional questions directed at presence of hypertension, depression, asthma, and gastroesophageal reflux disease (GERD) were added in the questionnaire.

HRQoL assessment
----------------

HRQoL was measured by Medical Outcomes Study Short Form-36 (SF-36) questionnaire which has been a well established instrument for HRQoL in OSA patients.[@b27-ppa-12-765] SF-36 is a multifunctional, non-disease specific, 36-question health survey that evaluates 8 domains of health providing an overall assessment of HRQoL. Health aspects that are being valued are physical functioning, physical role limitations, bodily pain, general health perception, social functioning, emotional role limitations, emotional well-being, and vitality. Each domain is scored on a 0 to 100 scale, with higher score indicating better HRQoL.[@b28-ppa-12-765] Validated Croatian version of the SF-36 questionnaire had been used.[@b29-ppa-12-765]

Statistical analysis
--------------------

Statistical software MedCalc (Mariakerke, Belgium; version 11.5.1.0) for Windows was used for statistical data analysis. Data were expressed as mean ± standard deviation for continuous variables and as whole numbers and percentage for categorical variables. Kolmogorov--Smirnov test has been used for normality of data distribution. Student's *t*-test was used for comparison of independent continuous data between groups with different risk for OSA. Chi-square test has been used for analysis of gender differences and comorbidites presence between groups with different risk for OSA. Pearson correlation served for assessment of correlation between SF-36 variables and other variables. Multiple linear regression analysis with stepwise selection algorithm was used to determine the relative importance of independent variables (STOP score, body mass index \[BMI\], age, HbA1c, and T2DM duration) in prediction of SF-36 parameters. Variables that did not reach statistical significance were excluded from the model. The statistical significance was defined as *P*\<0.05.

Results
=======

Sample characteristics
----------------------

Our sample comprised a total of 466 subjects; of them, 47.8% were male subjects. Mean age of our population was 66.3±7.7 years, while mean BMI was 28.7±2.0 kg/m^2^. Furthermore, mean HbA1c value of our study sample was 7.9%±1.8% and mean T2DM duration was 13.2±9.4 years ([Table 1](#t1-ppa-12-765){ref-type="table"}).

Mean STOP score of our sample was 2.1±1.1. Therefore, most subjects (N=312, 67.0%) represented high-risk OSA group based on STOP questionnaire. High-risk OSA group exhibited higher BMI (29.6±5.1 vs 27.0±4.4 kg/m^2^, *P*\<0.001), neck circumference (38.2±5.0 vs 37.1±3.7 cm, *P*=0.003), waist circumference (103.7±13.8 vs 98.2±12.2 cm, *P*\<0.001), ESS score (6.5±4.5 vs 4.0±3.3, *P*\<0.001), and duration of T2DM (14.3±9.2 vs 11.0±5.0 years, *P*\<0.001). There was no difference in other variables between groups ([Table 1](#t1-ppa-12-765){ref-type="table"}).

Comorbidities
-------------

Prevalence of arterial hypertension and asthma was significantly higher in subjects with high risk for OSA based on STOP questionnaire (93.0%, N=290 vs 44.2%, N=68, *P*\<0.001 and 10.9%, N=34 vs 5.2%, N=8, *P*=0.043, respectively). Furthermore, group with high risk for OSA exhibited higher prevalence of depression and GERD (12.2%, N=38 vs 9.1%, N=14, *P*=0.319 and 30.8%, N=96 vs 23.4%, N=36, *P*=0.096, respectively), but without statistical significance ([Table 2](#t2-ppa-12-765){ref-type="table"}).

Daytime sleepiness
------------------

Most patients represented low/normal daytime sleepiness (63.7%), followed by severe (20.0%) and finally moderate daytime sleepiness group (16.3%). Among high-risk OSA group, there were statistically significantly more subjects with ESS ≥7 (*P*\<0.001) ([Table 3](#t3-ppa-12-765){ref-type="table"}).

HRQoL analysis
--------------

High-risk OSA group exhibited significantly lower SF-36 scores in all health dimensions compared to low-risk OSA group of our sample based on STOP questionnaire (*P*\<0.001) ([Table 4](#t4-ppa-12-765){ref-type="table"}).

Furthermore, STOP score and BMI showed statistically significant negative correlation with all SF-36 dimensions (*P*\<0.001). Moreover, age was in statistically significant negative correlation with physical functioning (*r*=−0.30, *P*\<0.001), physical role limitations (*r*=−0.33, *P*\<0.001), bodily pain (*r*=−0.31, *P*\<0.001), emotional role limitations (*r*=−0.12, *P*=0.012), and vitality (*r*=−0.29, *P*\<0.001). In addition, ESS score exhibited significant negative correlation with general health perception (*r*=−0.20, *P*\<0.001) and social functioning (*r*=−0.13, *P*=0.005). Finally, HbA1c significantly correlated only with vitality domain (*r*=−0.19, *P*\<0.001), while T2DM duration and insulin therapy duration showed statistically significant correlation with most SF-36 components except emotional role limitations and social functioning, as well as physical role limitations, emotional role limitations, and general health perception ([Table 5](#t5-ppa-12-765){ref-type="table"}).

Based on multiple linear regression model, STOP score was confirmed as statistically significant independent predictor for all SF-36 components, adjusted for BMI, age, HbA1c, and T2DM duration (*P*\<0.001). Furthermore, STOP score was the strongest predictor of social functioning, emotional role limitations, and emotional well-being ([Table 6](#t6-ppa-12-765){ref-type="table"}).

Discussion
==========

Findings from our study demonstrate that high proportion of T2DM patients have high risk for OSA. Furthermore, we observed that group with high risk for OSA has lower HRQoL in all SF-36 dimensions compared to low-risk patients. While it has been previously shown that diabetic patients with comorbidities such as depression and cardiovascular disorders have impaired HRQoL, limited evidence exists regarding the influence of concomitant OSA on HRQoL in T2DM population.[@b30-ppa-12-765] As far as we know, to this date only one recent polysomnography-assisted study questioned HRQoL in T2DM subjects with concurrent OSA.[@b12-ppa-12-765] However, whether high risk for OSA represents aggravating factor in HRQoL was unknown. To our knowledge, this is the first questionnaire-based study examining the influence of OSA risk on HRQoL in adult subjects with T2DM.

HRQoL imposes as an important clinical outcome in therapeutic approach to patients with T2DM as suggested in recent guidelines.[@b31-ppa-12-765] Available studies report that most individuals with T2DM have impaired HRQoL.[@b16-ppa-12-765] Furthermore, sleep quality, which is a significant predictor of HRQoL, is poorer in diabetic population.[@b23-ppa-12-765] Study by Luyster and Dunbar-Jacob showed that poor sleep quality unfavorably alters all health dimensions of SF-36.[@b22-ppa-12-765] It has been previously established that main features of OSA adversely affect individual's sleep quality and HRQoL.[@b24-ppa-12-765] However, available studies do not provide consistent results regarding the influence of OSA severity on HRQoL.[@b24-ppa-12-765],[@b32-ppa-12-765] Still, recent related study on T2DM patients by Bironneau et al showed lower vitality, physical role functioning, and social functioning components of SF-36 with increasing OSA severity in recruited population.[@b12-ppa-12-765] Our findings are comparable with aforementioned study; however, we obtained significantly lower SF-36 scores in all health dimensions in high-risk OSA group. Additionally, we found significant negative correlation of STOP score with all SF-36 dimension scores. After adjustment for BMI, age, HbA1c, and T2DM duration in multiple regression model, STOP score maintained statistical significance as an independent predictor of SF-36 parameters. Having in mind that diabetic patients have impaired HRQoL per se, consequences of these HRQoL deteriorations are yet to be recognized.[@b16-ppa-12-765]

There are evidences that better glycemic control improves HRQoL.[@b17-ppa-12-765] However, HbA1c values from our study did not show statistically significant negative correlation with most of the SF-36 dimensions, except with vitality. Furthermore, Kent et al showed that concomitant OSA impairs glycemic control in T2DM patients.[@b8-ppa-12-765] Similarly, Aronsohn et al demonstrated higher HbA1c values among T2DM population with concomitant OSA compared to other diabetic patients.[@b13-ppa-12-765] However, in our multiple regression model, HbA1c lacked statistical significance as an independent predictor of SF-36 parameters, except for physical role limitations. Nonetheless, we did not find statistically significant difference in HbA1c values between different OSA risk groups.

Important to notice is that there was no statistically significant difference in depression prevalence between high-risk and low-risk OSA groups. In a study by Wexler et al, depression was the strongest correlate associated with reduced HRQoL in T2DM patients.[@b20-ppa-12-765] Similarly, there was no significant difference in GERD prevalence between our high-risk and low-risk OSA groups. However, total prevalence was still higher than expected in general population.[@b33-ppa-12-765] On contrary, coexistence of arterial hypertension and asthma, which are a well-established comorbidities of both T2DM and OSA, was significantly higher among high-risk OSA group in our study. Most available studies provide evidence about negative effects of arterial hypertension on HRQoL in diabetic patients, especially after the development of well-known complications.[@b16-ppa-12-765] However, some authors did not find significant correlation of arterial hypertension with HRQoL.[@b20-ppa-12-765]

Furthermore, a previous study had shown that sleepiness may lead to significant difficulties in everyday functioning and HRQoL.[@b15-ppa-12-765] Group with high risk for OSA from our study exhibited significantly higher daytime sleepiness compared to low-risk group. Even though Silva et al showed that daytime sleepiness is an important predictor of HRQoL, our analysis revealed negative correlation of ESS score only with general health perception and social functioning components of SF-36.[@b27-ppa-12-765]

It has been formerly shown that aging impairs HRQoL in T2DM patients.[@b20-ppa-12-765] Consistently, we found significant negative correlation of age with physical functioning, physical role limitations, bodily pain, emotional role limitations, and vitality of SF-36 questionnaire. Moreover, multiple regression model confirmed age as a statistically significant predictor of mentioned SF-36 variables. In fact, age was the strongest predictor of abovementioned variables except for emotional role limitations. These results suggest higher correlation of age with physical dimensions of HRQoL which is reasonable mainly due to physiologic changes, as well as longer disease duration in most patients. Similar findings were described by Klein et al while there are evidences about inverse correlation of HRQoL with age.[@b34-ppa-12-765],[@b35-ppa-12-765] Latter could be due to skeptical approach to chronic disease in younger patients. However, most subjects from our study were older than 60 years and therefore could have more mature view on the disease, allowing for the physical difficulties to mainly affect HRQoL. Moreover, there are evidences about sex differences in HRQoL.[@b36-ppa-12-765] Importantly, our sample was evenly representated with both sex and age and there was no statistically significant difference in age and gender between high-risk and low-risk OSA group.

High-risk OSA group from our sample exhibited significantly higher BMI values compared to low-risk group. Obesity has been already shown to have independent adverse effect on HRQoL.[@b21-ppa-12-765] Likewise, our analysis showed significant negative correlation of BMI with all SF-36 categories. However, in multiple regression analysis, BMI lacked statistical significance as predictor of emotional role limitations and emotional well-being components of SF-36. Interestingly, Wexler et al did not find a relationship between obesity and decreased HRQoL.[@b20-ppa-12-765]

Groups with high and low risk for OSA from our study statistically significantly differed in T2DM duration. Moreover, T2DM duration showed significant negative correlation with most SF-36 components, except social functioning and emotional role limitations. Similar influence of T2DM duration on HRQoL expressed by Health Utility Index-III was obtained by Wexler et al.[@b20-ppa-12-765] However, in our multiple regression analysis, T2DM duration lacked statistical significance in prediction of SF-36 components, except in weak prediction of general health perception. Furthermore, insulin use has mostly been reported as a negative factor in HRQoL of diabetic patients.[@b20-ppa-12-765] Similarly, our analysis revealed negative correlation with several components of SF-36. However, groups with high and low risk for OSA from our study did not significantly differ in insulin use or in duration of insulin therapy.

Together with preceding findings, present analysis confirmed that high proportion of patients with T2DM have high risk for OSA. As much as 67% of our sample stands for high-risk OSA group based on STOP questionnaire. It has been well-established that patients with T2DM have increased risk for OSA, as well as increased prevalence of OSA, compared to general population. Previous questionnaire-based studies examining the risk for OSA in T2DM patients reported high prevalence of high-risk OSA group in T2DM population.[@b10-ppa-12-765] These data are supported by multitude polysomnography-assisted research which reassure increased OSA prevalence in T2DM population. One such study by Bironneau et al even reported OSA prevalence of 69% in diabetic patients.[@b12-ppa-12-765] Our findings are consistent with available studies confirming that a significant proportion of T2DM patients account for high-risk OSA group, which is much higher than expected in general population.

Additionally, it is interesting to remark that our sample had lower HRQoL in all SF-36 components in comparison with Croatian SF-36 norms, except for emotional well-being and vitality which were higher in our sample.[@b29-ppa-12-765]

Unrecognized significance of these results by health care profeşsionals is emphasized by Lecomte et al who showed that only 35% of T2DM patients with OSA-related symptoms have been already diagnostically evaluated for OSA.[@b37-ppa-12-765] Likewise, Heffner et al retrospectively detected considerable mismatch in actually diagnosed and expected OSA prevalence in more than 16,000 T2DM patients.[@b38-ppa-12-765] This highlights the importance of implementation of routine HRQoL assessment in specific populations, such as diabetic patients, which could highlight the patients with occult symptoms for further diagnostic procedures. Essentially, lower HRQoL in T2DM patients is associated with higher total mortality, independently of sex or age.[@b18-ppa-12-765] Most importantly, a recent meta-analysis by Kuhn et al demonstrated that CPAP therapy improves HRQoL, indicating the need for prompt screening, diagnosis, and management of OSA in diabetic patients.[@b39-ppa-12-765]

Similar to any other research study, this study has some limitations. Organization of this study was cross-sectional, so it was not possible to establish any causal relationship. Furthermore, it was a questionnaire-based study, which is feasible for response bias. Moreover, the questionnaire used for HRQoL was not disease specific but rather a generic instrument (SF-36). Therefore, combination of generic with disease-specific questionnaire could be more comprehensive.

Conclusion
==========

Our study has shown that T2DM patients with high risk for OSA have lower HRQoL compared to low-risk group, as examined by SF-36 questionnaire. Additionally, we have confirmed that among diabetic population, there is high proportion of patients with high risk for OSA.
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###### 

Comparison of characteristics between groups with different risk for OSA based on STOP questionnaire

  Parameter                          Total (n=466)   Low-risk OSA group (STOP \<2; n=154)   High-risk OSA group (STOP ≥2; n=312)   *P*-value[a](#tfn2-ppa-12-765){ref-type="table-fn"}
  ---------------------------------- --------------- -------------------------------------- -------------------------------------- -----------------------------------------------------
  Age (years)                        66.3±7.7        65.7±11.5                              66.6±10.3                              0.388
  Male gender                        223 (47.9%)     82 (53.2%)                             141 (45.2%)                            0.101
  Body weight (kg)                   85.0±17.4       80.2±15.5                              87.4±17.8                              \<0.001
  Body height (cm)                   171.7±9.9       172.0±10.1                             171.6±9.8                              0.684
  BMI (kg/m^2^)                      28.7±2.0        27.0±4.4                               29.6±5.1                               \<0.001
  Neck circumference (cm)            37.9±4.7        37.1±3.7                               38.2±5.0                               0.003
  Waist circumference (cm)           101.9±13.5      98.2±12.2                              103.7±13.8                             \<0.001
  T2DM duration (years)              13.2±9.4        11.0±5.0                               14.3±9.2                               \<0.001
  HbA1c (%)                          7.9±1.8         7.7±1.8                                8.0±1.8                                0.074
  STOP score                         2.1±1.1         0.8±0.4                                2.7±0.7                                \<0.001
  ESS score                          5.7±4.4         4.0±3.3                                6.5±4.5                                \<0.001
  Insulin use                        215 (46.1%)     67 (43.5%)                             148 (47.4%)                            0.423
  Insulin therapy duration (years)   3.4±6.8         2.3±9.5                                3.9±7.5                                0.054
  History of car accident            74 (15.9%)      19 (12.3%)                             55 (17.6%)                             0.142

**Notes:** Data are presented as mean ± standard deviation for quantitative variables and as number and percentage for qualitative variables;

Student's *t*-test for quantitative variables and chi-square test for qualitative variables.

**Abbreviations:** BMI, body mass index; HbA1c, glycated hemoglobin; T2DM, diabetes mellitus type 2; STOP, Snoring, Tiredness, Observed apnea, and high blood Pressure; ESS, Epworth Sleepiness Scale; OSA, obstructive sleep apnea.

###### 

Comparison of comorbidites between groups with different risk for OSA based on STOP questionnaire

  Parameter               Total (n=466)   Low-risk OSA group (STOP \<2; n=154)   High-risk OSA group (STOP ≥2; n=312)   *P*-value[a](#tfn5-ppa-12-765){ref-type="table-fn"}
  ----------------------- --------------- -------------------------------------- -------------------------------------- -----------------------------------------------------
  Asthma                  42 (9.0%)       8 (5.2%)                               34 (10.9%)                             0.043
  Depression              52 (11.2%)      14 (9.1%)                              38 (12.2%)                             0.319
  GERD                    132 (28.3%)     36 (23.4%)                             96 (30.8%)                             0.096
  Arterial hypertension   358 (76.8%)     68 (44.2%)                             290 (93.0%)                            \<0.001

**Notes:** Data are presented as number and percentage;

chi-square test.

**Abbreviations:** OSA, obstructive sleep apnea; STOP, Snoring, Tiredness, Observed apnea, and high blood Pressure; GERD, gastroesophageal reflux disease.

###### 

Comparison of daytime sleepiness based on ESS score between groups with different risk for OSA based on STOP questionnaire

  Parameter   Total (n=466)   Low-risk OSA group (STOP \<2; n=154)   High-risk OSA group (STOP ≥2; n=312)   *P*-value[a](#tfn8-ppa-12-765){ref-type="table-fn"}
  ----------- --------------- -------------------------------------- -------------------------------------- -----------------------------------------------------
  ESS ≤6      297 (63.7%)     131 (85.1%)                            166 (53.2%)                            \<0.001
  ESS =7--8   76 (16.3%)      10 (6.5%)                              66 (21.2%)                             
  ESS ≥9      93 (20.0%)      13 (8.4%)                              80 (25.6%)                             

**Notes:** Data are presented as number and percentage;

chi-square test.

**Abbreviations:** ESS, Epworth Sleepiness Scale; OSA, obstructive sleep apnea; STOP, Snoring, Tiredness, Observed apnea, and high blood Pressure.

###### 

Comparison of SF-36 variables between groups with different risk for OSA based on STOP questionnaire

  Parameter                    Total (n=466)   Low-risk OSA group (STOP \<2; n=154)   High-risk OSA group (STOP ≥2; n=312)   *P*-value[a](#tfn11-ppa-12-765){ref-type="table-fn"}
  ---------------------------- --------------- -------------------------------------- -------------------------------------- ------------------------------------------------------
  Physical functioning         61.7±40.1       73.6±31.2                              55.8±32.4                              \<0.001
  Physical role limitations    46.8±49.9       58.4±42.7                              41.1±41.9                              \<0.001
  Bodily pain                  51.6±27.6       67.2±28.3                              50.8±29.3                              \<0.001
  General health perception    41.2±29.4       45.9±15.0                              38.8±17.4                              \<0.001
  Social functioning           65.7±32.8       75.2±23.2                              62.5±24.6                              \<0.001
  Emotional role limitations   52.5±50.0       61.7±42.9                              48.0±46.8                              \<0.001
  Emotional well-being         66.7±28.1       65.2±16.51                             56.2±16.9                              \<0.001
  Vitality                     59.2±24.0       66.5±25.8                              50.1±27.1                              \<0.001

**Notes:** Data are presented as mean ± standard deviation;

Student's *t*-test for independent samples.

**Abbreviations:** OSA, obstructive sleep apnea; STOP, Snoring, Tiredness, Observed apnea, and high blood Pressure; SF-36, Medical Outcomes Study Short Form-36.

###### 

Pearson's correlation between SF-36 parameters and selected variables

  Parameter                    STOP score        ESS score         BMI, kg/m^2^      Age, years        T2DM duration, years   Insulin therapy duration, years   HbA1c
  ---------------------------- ----------------- ----------------- ----------------- ----------------- ---------------------- --------------------------------- -----------------
  Physical functioning         −0.29 (\<0.001)   −0.002 (0.957)    −0.23 (\<0.001)   −0.30 (\<0.001)   −0.12 (0.011)          −0.11 (0.020)                     −0.05 (0.321)
  Physical role limitations    −0.26 (\<0.001)   −0.08 (0.080)     −0.18 (\<0.001)   −0.33 (\<0.001)   −0.12 (0.008)          −0.08 (0.078)                     −0.07 (0.129)
  Bodily pain                  −0.32 (\<0.001)   −0.04 (0.393)     −0.22 (\<0.001)   −0.31 (\<0.001)   −0.12 (0.011)          −0.10 (0.032)                     −0.04 (0.360)
  General health perception    −0.26 (\<0.001)   −0.20 (\<0.001)   −0.23 (\<0.001)   −0.07 (0.113)     −0.17 (\<0.001)        −0.08 (0.096)                     −0.03 (0.536)
  Social functioning           −0.31 (\<0.001)   −0.13 (0.005)     −0.20 (\<0.001)   −0.03 (0.492)     −0.09 (0.050)          −0.09 (0.044)                     −0.08 (0.105)
  Emotional role limitations   −0.20 (\<0.001)   0.008 (0.860)     −0.10 (0.031)     −0.12 (0.012)     −0.03 (0.464)          −0.04 (0.397)                     0.02 (0.746)
  Emotional well-being         −0.29 (\<0.001)   −0.09 (0.054)     −0.09 (0.042)     −0.01 (0.945)     −0.14 (0.002)          −0.11 (0.015)                     −0.08 (0.077)
  Vitality                     −0.33 (\<0.001)   −0.05 (0.242)     −0.22 (\<0.001)   −0.29 (\<0.001)   −0.13 (0.005)          −0.10 (0.024)                     −0.19 (\<0.001)

**Notes:**

*R*-value indicates Pearson's correlation coefficient;

Pearson's correlation test.

**Abbreviations:** T2DM, diabetes mellitus type 2; HbA1c, glycated hemoglobin; BMI, body mass index; STOP, Snoring, Tiredness, Observed apnea, and high blood Pressure; ESS, Epworth Sleepiness Scale; SF-36, Medical Outcomes Study Short Form-36.

###### 

Multiple linear regression analysis of STOP score and selected variables as independent predictors of SF-36 parameters

  Parameter                    STOP score              BMI, kg/m^2^                                    Age, years                                      HbA1c, %                                        T2DM duration, years                            Overall
  ---------------------------- ----------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------------
  Physical functioning         −6.37 (−4.80) \<0.001   −1.40 (−4.77) \<0.001                           −0.99 (−7.58) \<0.001                           ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   *R*^2^ adjusted =0.201 *F* ratio =39.93 *P*\<0.001
  Physical role limitations    −7.21 (−4.16) \<0.001   −1.43 (−3.72) \<0.001                           −1.44 (−8.43) \<0.001                           −2.15 (−2.15) 0.032                             ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   *R*^2^ adjusted =0.196 *F* ratio =29.41 *P*\<0.001
  Bodily pain                  −6.70 (−5.61) \<0.001   −1.15 (−4.36) \<0.001                           0.91 (−7.80) \<0.001                            ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   *R*^2^ adjusted =0.216 *F* ratio =43.70 *P*\<0.001
  General health perception    −2.56 (−3.44) \<0.001   −0.65 (−4.08) \<0.001                           ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   −0.28 (−3.35) \<0.001                           *R*^2^ adjusted =0.108 *F* ratio =19.84 *P*\<0.001
  Social functioning           −6.12 (−5.80) \<0.001   −0.57 (−2.47) 0.014                             ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   *R*^2^ adjusted =0.102 *F* ratio =27.46 *P*\<0.001
  Emotional role limitations   −8.14 (−4.28) \<0.001   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   −0.46 (−2.39) 0.017                             ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   *R*^2^ adjusted =0.047 *F* ratio =12.47 *P*\<0.001
  Emotional well-being         −4.61 (−6.57) \<0.001   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   *R*^2^ adjusted =0.083 *F* ratio =43.11 *P*\<0.001
  Vitality                     −6.64 (−6.00) \<0.001   −1.01 (−4.12) \<0.001                           −0.80 (−7.33) \<0.001                           ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   ns[c](#tfn18-ppa-12-765){ref-type="table-fn"}   *R*^2^ adjusted =0.212 *F* ratio =42.65 *P*\<0.001

**Notes:**

*B*-value indicates regression coefficient of the independent variable;

*t*-value indicates *t*-statistic value;

variables were not included in the model due to statistical insignificance.

**Abbreviations:** T2DM, diabetes mellitus type 2; BMI, body mass index; STOP, Snoring, Tiredness, Observed apnea, and high blood Pressure; SF-36, Medical Outcomes Study Short Form-36; HbA1c, glycated hemoglobin; ns, not significant.
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